The GTC Method: How Our Gene Therapy Consulting Works

Q: What are GTC's Intelligent Platforms?

VIP, PIP, CIP, CLIP, RIP and COIN are structured knowledge engines that deconstruct every facet of gene therapy development. They are continuously updated and human-curated, so the AI agents built on them answer from a single source of truth.

Q: Does GTC replace a CDMO, CRO or regulatory counsel?

No. GTC provides desk-based, evidence-led decision support: comparing candidates and platforms, modelling dose and cost scenarios, and building lean development roadmaps. It does not replace a CDMO, a CRO, a Qualified Person, or qualified legal and regulatory counsel, and is not a substitute for their scope of work.

The Foundation of Our Approach

Two integrated pillars powered by proprietary AI infrastructure

AI-Powered Strategic Intelligence

Transform high-stakes decision-making with AI agents that leverage our proprietary Intelligent Platforms to provide hyper-specialized, actionable insights for critical go/no-go decisions.

Click to explore our Proprietary Intelligent Platforms that power this intelligence →

AI-Driven Operational Excellence

Systematically eliminate "cash leaks" through AI workflow automations, custom agents, and RAG systems that streamline communication, documentation, and project management.

Click to see how we implement AI to remove operational hurdles →

The Foundation: Proprietary Intelligent Platforms

Our "Single Source of Truth" that powers reliable AI analysis

Not Just Databases—Knowledge Engines

Our Intelligent Platforms (VIP, PIP, CIP, CLIP, RIP, COIN) are structured knowledge engines that deconstruct every facet of gene therapy development. These continuously updated, human-curated systems provide the reliable foundation that enables our AI agents to deliver insights traditional consultancies simply cannot match.

VIP

Vector Intelligence Platform

Core Question: "Which vector will deliver the best therapeutic outcome for this specific target and indication?"

Comprehensive database of viral vectors, serotypes, and performance characteristics across different tissues and applications.

Vector performance analytics
Tissue-specific tropism data
Manufacturing considerations
Regulatory precedents
Competitive landscape mapping

PIP

Preclinical Intelligence Platform

Core Question: "What is the most efficient and effective path to get this drug safely into human trials?"

Comprehensive repository of preclinical study designs, safety endpoints, dose-response relationships, and IND-enabling requirements across gene therapy programs.

IND-enabling study optimization
Safety assessment frameworks
Dose selection strategies
Regulatory readiness evaluation
Risk mitigation protocols

CIP

CMC Intelligence Platform

Core Question: "How can this drug be made reliably, scalably, and compliantly?"

Detailed database of manufacturing processes, analytical methods, quality control specifications, and scale-up strategies from research through commercial production.

Manufacturing process optimization
Scale-up strategy development
Quality control frameworks
Supply chain intelligence
Regulatory compliance assurance

CLIP

Clinical Intelligence Platform

Core Question: "What is the optimal clinical strategy to demonstrate safety and efficacy while minimizing risk and timeline?"

Structured analysis of clinical trials, outcomes, and regulatory interactions across the gene therapy landscape.

Trial design optimization
Endpoint selection guidance
Regulatory pathway analysis
Safety profile benchmarking
Market access insights

RIP

Regulatory Intelligence Platform

Core Question: "What do the regulators expect, and how can we proactively meet their standards to ensure the fastest, smoothest path to approval?"

Extensive collection of regulatory guidance documents, FDA/EMA meeting minutes, approval packages, and submission requirements specific to gene therapy products.

Regulatory pathway optimization
FDA/EMA interaction strategies
Submission requirement mapping
Approval precedent analysis
Regulatory risk assessment

COIN

Commercial Intelligence Platform

Core Question: "How does this drug become a successful business, not just a scientific achievement?"

Comprehensive market intelligence covering competitive landscapes, pricing strategies, reimbursement pathways, and go-to-market approaches for gene therapy products.

Market opportunity assessment
Competitive positioning analysis
Reimbursement strategy development
Go-to-market planning
Commercial viability modeling

The Integrated Advantage

Our platforms don't operate in isolation—they're designed to cross-reference and inform each other, providing a holistic view that enables AI-powered insights across the entire gene therapy development lifecycle.

How We Implement AI to remove Operational Hurdles

A systematic approach to AI transformation

01

Intelligence Assessment

We audit your current information systems, decision-making processes, and operational workflows to identify optimization opportunities.

Timeline: 1-2 weeks
Output: AI Transformation Roadmap

02

Workflow Automation

We implement AI-driven workflows for your highest-impact operational processes, starting with quick wins and expanding systematically.

Timeline: 4-8 weeks
Output: Automated Operational Systems

03

Knowledge Transfer

We train your team to maintain and expand the AI systems, ensuring sustainable transformation beyond our engagement.

Timeline: 2-4 weeks
Output: Internal AI Capabilities

Why The GTC Method Works

Built for the unique challenges of gene therapy development

Traditional Consulting Limitations

Human-Capital Intensive: Limited by consultant availability and expertise
Static Deliverables: Reports become outdated quickly
Broad Focus: Generic frameworks that don't capture gene therapy nuances
Reactive Approach: Called in when problems are already apparent
High Cost Per Insight: Every analysis requires significant manual effort

The GTC Method Advantages

AI-Augmented Scale: Deploy insights at the speed and scale of software
Living Intelligence: Continuously updated platforms and real-time insights
Gene Therapy Specialization: Purpose-built for cell & gene therapy development challenges
Proactive Monitoring: Early warning systems prevent problems before they occur
Exponential Efficiency: Marginal cost of additional insights approaches zero

The Six Intelligent Platforms

The six GTC Intelligent Platforms and the question each one answers
Platform	Core question it answers
VIP (Vector Intelligence Platform)	Which vector will deliver the best therapeutic outcome for this specific target and indication?
PIP (Preclinical Intelligence Platform)	What is the most efficient and effective path to get this drug safely into human trials?
CIP (CMC Intelligence Platform)	How can this drug be made reliably, scalably, and compliantly?
CLIP (Clinical Intelligence Platform)	What is the optimal clinical strategy to demonstrate safety and efficacy while minimizing risk and timeline?
RIP (Regulatory Intelligence Platform)	What do the regulators expect, and how can we proactively meet their standards to ensure the fastest, smoothest path to approval?
COIN (Commercial Intelligence Platform)	How does this drug become a successful business, not just a scientific achievement?

Frequently asked questions about the GTC Method

What is the GTC Method?

What are GTC's Intelligent Platforms?

Does GTC replace a CDMO, CRO or regulatory counsel?

Ready to Implement The GTC Method?

Transform your gene therapy program with AI-powered intelligence and operational excellence. See how our systematic approach can extend your runway and accelerate your path to the clinic.

Book a Free Discovery Call Explore Services